Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HIV Preventive Vaccine”

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00991354
What this trial is testing

Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 48
Early research (Phase 1)Study completedNCT01054872
What this trial is testing

Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 8
Early research (Phase 1)Study completedNCT00545987
What this trial is testing

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

Who this might be right for
HIV Infections
Rockefeller University 40
Early research (Phase 1)Study completedNCT00119873
What this trial is testing

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 48
Testing effectiveness (Phase 2)Study completedNCT02564523
What this trial is testing

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Who this might be right for
Hemorrhagic Fever, Ebola
Janssen Vaccines & Prevention B.V. 1,075
Early research (Phase 1)Ended earlyNCT01441193
What this trial is testing

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

Who this might be right for
HIV Infection
Barbara Ensoli, MD 11
Early research (Phase 1)Study completedNCT00056745
What this trial is testing

Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 12
Not applicableStudy completedNCT04711265
What this trial is testing

Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

Who this might be right for
HPV VaccineHPV InfectionHIV-1-infection
Kenya Medical Research Institute 176
Testing effectiveness (Phase 2)Study completedNCT00071851
What this trial is testing

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 180
Not applicableStudy completedNCT00029744
What this trial is testing

Prepare for Future HIV Vaccine Studies

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
Early research (Phase 1)Study completedNCT00000968
What this trial is testing

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 60
Testing effectiveness (Phase 2)Study completedNCT00000871
What this trial is testing

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 420
Not applicableStudy completedNCT00000866
What this trial is testing

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 36
Early research (Phase 1)Study completedNCT00051922
What this trial is testing

Development of a New HIV Vaccine

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 24
Early research (Phase 1)Study completedNCT00000853
What this trial is testing

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 37
Early research (Phase 1)Study completedNCT00000683
What this trial is testing

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 54
Not applicableStudy completedNCT01024764
What this trial is testing

Observational Study of the Preventive Trial With HIV-1 Tat Protein

Who this might be right for
Healthy Subjects
Istituto Superiore di Sanità 5
Early research (Phase 1)Study completedNCT00384787
What this trial is testing

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 90
Early research (Phase 1)Study completedNCT00000767
What this trial is testing

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 18
Early research (Phase 1)Study completedNCT00000746
What this trial is testing

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 56
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation